These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

237 related articles for article (PubMed ID: 2909265)

  • 41. Inefficient, corrupt, and unreliable. The system for testing treatments is in chaos.
    Fischer J
    US News World Rep; 2000 Aug; 129(8):50. PubMed ID: 11066829
    [No Abstract]   [Full Text] [Related]  

  • 42. Current status of quality in Japanese clinical trials.
    Saito K; Kodama Y; Ono S; Mutoh M; Kawashima S; Fujimura A
    Contemp Clin Trials; 2005 Aug; 26(4):503-9. PubMed ID: 16054582
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Interpreting HIV clinical trials.
    Glesby MJ
    AIDS Clin Care; 1999 Jul; 11(7):58-9. PubMed ID: 11366435
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Errors of methodology. General considerations seen by the cardiologist].
    Orzan F
    G Ital Cardiol; 1985 Jun; 15(6):625-7. PubMed ID: 4065482
    [No Abstract]   [Full Text] [Related]  

  • 45. Complexity and contradiction in clinical trial research.
    Horwitz RI
    Am J Med; 1987 Mar; 82(3):498-510. PubMed ID: 3548349
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Quality of reports of clinical trials submitted by the drug industry to the Finnish and Swedish control authorities.
    Hemminki E
    Eur J Clin Pharmacol; 1981 Feb; 19(3):157-65. PubMed ID: 7215412
    [TBL] [Abstract][Full Text] [Related]  

  • 47. International differences in cardiovascular clinical trials.
    O'Shea JC; Califf RM
    Am Heart J; 2001 May; 141(5):866-74. PubMed ID: 11320381
    [No Abstract]   [Full Text] [Related]  

  • 48. Criticism of tumor response criteria raises trial design questions.
    Twombly R
    J Natl Cancer Inst; 2006 Feb; 98(4):232-4. PubMed ID: 16478740
    [No Abstract]   [Full Text] [Related]  

  • 49. The double-blind in danger: untoward consequences of informed consent.
    Brownell KD; Stunkard AJ
    Am J Psychiatry; 1982 Nov; 139(11):1487-9. PubMed ID: 6753613
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Breast cancer. Methods in intensely criticized research project].
    Vesterdal A
    Sygeplejersken; 1988 Sep; 88(38):9. PubMed ID: 3217862
    [No Abstract]   [Full Text] [Related]  

  • 51. Reassessing the design, conduct, and analysis of clinical trials of therapy for community-acquired pneumonia.
    Powers JH
    Clin Infect Dis; 2008 Apr; 46(8):1152-6. PubMed ID: 18444849
    [No Abstract]   [Full Text] [Related]  

  • 52. Determining optimal therapy--randomized trials in individual patients.
    Smyth JA
    N Engl J Med; 1986 Sep; 315(12):767-8. PubMed ID: 3748088
    [No Abstract]   [Full Text] [Related]  

  • 53. Improvement of phase III psychotropic drug trials by intensive phase II work.
    Klein DF
    Neuropsychopharmacology; 1991 Jun; 4(4):251-8; discussion 259-71. PubMed ID: 1867735
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Independent data monitoring committees: rationale, operations and controversies.
    Ellenberg SS
    Stat Med; 2001 Sep 15-30; 20(17-18):2573-83. PubMed ID: 11523070
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Recommended guidelines for studies of human subjects with spinal cord injury.
    Anderson DK; Beattie M; Blesch A; Bresnahan J; Bunge M; Dietrich D; Dietz V; Dobkin B; Fawcett J; Fehlings M; Fischer I; Grossman R; Guest J; Hagg T; Hall ED; Houle J; Kleitman N; McDonald J; Murray M; Privat A; Reier P; Steeves J; Steward O; Tetzlaff W; Tuszynski MH; Waxman SG; Whittemore S; Wolpaw J; Young W; Zheng B
    Spinal Cord; 2005 Aug; 43(8):453-8. PubMed ID: 15824756
    [No Abstract]   [Full Text] [Related]  

  • 56. Placebo-controlled, double-blind trials.
    Walter E; Weber E
    Lancet; 1980 Jun; 1(8182):1363. PubMed ID: 6104156
    [No Abstract]   [Full Text] [Related]  

  • 57. Blinding during data analysis and writing of manuscripts.
    Gøtzsche PC
    Control Clin Trials; 1996 Aug; 17(4):285-90; discussion 290-3. PubMed ID: 8889343
    [No Abstract]   [Full Text] [Related]  

  • 58. The dangers of ad hoc protocols.
    Hanks GE
    J Clin Oncol; 1984 Oct; 2(10):1177-8. PubMed ID: 6491700
    [No Abstract]   [Full Text] [Related]  

  • 59. Bias in double-blind trials.
    Gøtzsche PC
    Dan Med Bull; 1990 Aug; 37(4):329-36. PubMed ID: 2245657
    [No Abstract]   [Full Text] [Related]  

  • 60. The management of interim analyses in drug development.
    Facey KM; Lewis JA
    Stat Med; 1998 Aug 15-30; 17(15-16):1801-9; discussion 1811-2. PubMed ID: 9749448
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.